Sanofi SA

Press Release: Sanofi and CD&R sign Opella share purchase agreement

19 Feb 2025 01:30:00 By Nasdaq GlobeNewswire

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

18 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

13 Feb 2025 14:08:49 By Nasdaq GlobeNewswire

Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

13 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Execution of a share buyback agreement for up to €2 billion

07 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi announces buy back of shares from L’Oréal

03 Feb 2025 01:30:00 By Nasdaq GlobeNewswire

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

31 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

30 Jan 2025 01:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - December 2024

29 Jan 2025 17:13:21 By Nasdaq GlobeNewswire

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

22 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Opella reaches study milestone for Cialis

21 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares – November 2024

15 Jan 2025 12:30:00 By Nasdaq GlobeNewswire

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

13 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

09 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

23 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

19 Dec 2024 12:00:00 By Nasdaq GlobeNewswire

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

17 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Press Release: Availability of the Q4 2024 Aide-mémoire

17 Dec 2024 01:30:00 By Nasdaq GlobeNewswire

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis

13 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US

11 Dec 2024 01:00:00 By Nasdaq GlobeNewswire